Breaking News Instant updates and real-time market news.

LGND

Ligand

$113.01

0.09 (0.08%)

, SNY

Sanofi

$46.65

0.25 (0.54%)

08:36
12/02/19
12/02
08:36
12/02/19
08:36

Ligand enters worldwide OmniAb platform license agreement with Sanofi

Ligand Pharmaceuticals (LGND) announces it has entered into a worldwide OmniAb license agreement with Sanofi (SNY). Under the agreement, Sanofi will be able to use Ligand's full OmniAb antibody discovery platform which includes OmniRat, OmniFlic, OmniMouse, OmniChicken and OmniClic in addition to Ligand's patented antigen technology. OmniAb is licensed to over 40 corporate partners globally, and this deal with Sanofi adds to a growing portfolio of OmniAb discovery and clinical development programs with global fully-integrated pharmaceutical companies. Sanofi will pay Ligand an up-front platform access fee, development and regulatory milestone payments and potential royalties on sales of marketed products.

LGND

Ligand

$113.01

0.09 (0.08%)

SNY

Sanofi

$46.65

0.25 (0.54%)

  • 07

    Dec

  • 09

    Dec

LGND Ligand
$113.01

0.09 (0.08%)

07/30/19
HCWC
07/30/19
NO CHANGE
Target $214
HCWC
Buy
Ligand shares weak on RVT-1502 update, says H.C. Wainwright
H.C. Wainwright analyst Joseph Pantginis attributes the post-earnings selloff today in shares of Ligand Pharmaceuticals to the company's update on RVT-1502. As part of its quarterly update this morning, Ligand indicated its belief that development of RVT-1502 with partner Metavant in the U.S. is highly unlikely to occur for diabetes, Pantginis tells investors in a research note. The analyst believes this clarity is responsible for today's share weakness but he points out that he's already incorporated this news into his valuation. On May 3 Pantginis removed the asset from his valuation, which lowered his price target for Ligand to the current $214. However, the company's growing OmniAb "juggernaut" continues to not be valued, and is a "company and franchise unto itself," says the analyst. He reiterates a Buy rating on Ligand Pharmaceuticals.
09/19/19
LEHM
09/19/19
UPGRADE
Target $132
LEHM
Overweight
Ligand upgraded to Overweight from Equal Weight at Barclays
Barclays analyst Balaji Prasad upgraded Ligand Pharmaceuticals to Overweight from Equal Weight and raised his price target for the shares to $132 from $110.
09/19/19
LEHM
09/19/19
UPGRADE
Target $132
LEHM
Overweight
Ligand upgraded to Overweight on pipeline potential at Barclays
As previously reported, Barclays analyst Balaji Prasad upgraded Ligand to Overweight from Equal Weight as he believes greater clarity on its pipeline offers strong support for its revenue potential and he revised his revenue forecasts for FY19-FY23 due to increased royalty estimates. The analyst pointed toward the upcoming sNDA for Baxdela IV in community-acquired bacterial pneumonia and Sparsentan topline Phase 3 data in FSGS, expected in the second half of 2020, as events to watch. Additionally, new Phase 3 data on Kyprolis + Darzalex may increase overall prescription levels, said Prasad, who also sees an improved risk/reward following the stock's recent underperformance compared to the NYSE ARCA Pharma Index. Prasad raised his price target for Ligand shares to $132 from $110.
09/19/19
09/19/19
UPGRADE

Fly Intel: Top five analyst upgrades
Catch up on today's top five analyst upgrades with this list compiled by The Fly: 1. Hyatt (H) upgraded to Buy from Neutral at Goldman Sachs with analyst Stephen Grambling saying the company is moving more aggressively towards asset light model, which should drive free cash flow and a re-rating in the shares. 2. Ligand (LGND) upgraded to Overweight from Equal Weight at Barclays with analyst Balaji Prasad saying he believes greater clarity on its pipeline offers strong support for its revenue potential and he revised his revenue forecasts for FY19-FY23 due to increased royalty estimates. 3. Twilio (TWLO) upgraded to Overweight from Equal Weight at Morgan Stanley with analyst Meta Marshall saying the company is building out a next-generation communication platform, with multiple expansion markets "still in their infancy." 4. KKR (KKR) upgraded to Conviction Buy from Buy at Goldman Sachs with analyst Alexander Blostein saying KKR is entering a period of accelerated earnings growth, driven by its upcoming fund-raising cycle and maturing investment portfolio, which should yield above-consensus incentive income and earnings. 5. Cousins Properties (CUZ) upgraded to Outperform from Market Perform at Wells Fargo with analyst Blaine Heck saying the company's share underperformance year-to-date relative to peers is not warranted given its exposure to office markets that should see solid rent growth over the next 12-24 months. This list is just a portion of The Fly's full analyst coverage. To see The Fly's full Street Research coverage, click here.
SNY Sanofi
$46.65

0.25 (0.54%)

09/23/19
GUGG
09/23/19
UPGRADE
GUGG
Buy
Sanofi upgraded to Buy on Dupixent's accelerating uptake at Guggenheim
Guggenheim analyst Seamus Fernandez upgraded Sanofi (SNY) to Buy from Neutral based on his view that Dupixent's accelerating uptake across Asthma and Atopic Dermatitis, and several other indications, should drive earlier than expected profitability of the Regeneron (REGN) antibody collaboration. He also believes that emerging markets growth should help stabilize the large established products and overall diabetes franchises and thinks that vaccines business growth looks sustainable. Fernandez, who also thinks pipeline expectations seem low, set a EUR96 price target on Sanofi shares.
09/23/19
GUGG
09/23/19
UPGRADE
Target $403
GUGG
Buy
Guggenheim upgrades Regeneron to Buy, says sentiment too negative
As previously reported, Guggenheim upgraded Regeneron (REGN) to Buy from Neutral as analyst Yatin Suneja noted that Eylea has maintained its dominance in the branded anti-VEGF retinal disease market despite "stiff branded competition" from Roche's (RHHBY) Lucentis and off-label use of Roche's Avastin. Eylea's expansion into new indications has resulted in a diversified business and defensible market position, argued Suneja, who also believes the Street is substantially under-appreciating the market opportunity for Dupixent, which is expected to drive significant leverage in the Sanofi (SNY) antibody collaboration that recently became profitable. Suneja raised the price target on Regeneron shares to $403 from $355.
10/02/19
STFL
10/02/19
NO CHANGE
Target $45
STFL
Buy
Stifel remains buyer of Principia Biopharma into Q4 data readouts
Stifel analyst Derek Archila remains bullish and a buyer of Principia Biopharma (PRNB) shares ahead of the company's two Phase 2 readouts for PRN1008 in immune thrombocytopenia and pemphigus vulgaris. The shares could reach the mid-$50 range if results are positive, Archila tells investors in a research note. He believes the bogey for each study is not that high and keeps a Buy rating on Principia with a $45 price target. The two clinical catalysts, coupled with Phase 2 data expected in the first half of 2020 from the company's partnered program with Sanofi (SNY) in multiple sclerosis, offers "multiple shots for valuation creation" over the next nine months.
10/15/19
BOFA
10/15/19
NO CHANGE
BOFA
Europe 1 List changes at BofA/Merrill
BofA/Merrill added Roche (RHHBY) and Sanofi (SNY) to the Europe 1 List and removed AstraZeneca.

TODAY'S FREE FLY STORIES

TNDM

TNDM

11:34
12/13/19
12/13
11:34
12/13/19
11:34
Hot Stocks
Breaking Hot Stocks news story on TNDM »

Tandem Diabetes trading…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

TLRY

Tilray

$18.70

-0.17 (-0.90%)

11:31
12/13/19
12/13
11:31
12/13/19
11:31
Conference/Events
Tilray conference call will now be held on December 18 hosted by Benchmark »

Cannabis Analyst Hickey…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 16

    Dec

ET

Energy Transfer LP

$12.51

-0.15 (-1.19%)

11:25
12/13/19
12/13
11:25
12/13/19
11:25
Options
Energy Transfer call volume above normal and directionally bullish »

Bullish option flow…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 23

    Mar

OGI

Organigram

$2.60

0.035 (1.36%)

11:25
12/13/19
12/13
11:25
12/13/19
11:25
Conference/Events
Organigram management to meet with Cantor Fitzgerald »

Analyst Pablo Zuanic…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 13

    Dec

CNP

CenterPoint Energy

$25.47

0.64 (2.58%)

11:19
12/13/19
12/13
11:19
12/13/19
11:19
Periodicals
CenterPoint Energy in talks to settle on Texas rates, Bloomberg says »

Bloomberg cites a filing…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

SPT

Sprout Social

$0.00

(0.00%)

11:18
12/13/19
12/13
11:18
12/13/19
11:18
Syndicate
Breaking Syndicate news story on Sprout Social »

Sprout Social indicated…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 13

    Dec

$NSD

NASDAQ Market Internals

$0.00

(0.00%)

11:17
12/13/19
12/13
11:17
12/13/19
11:17
Technical Analysis
NASDAQ market internals summary »

Volume is above average…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

$NYE

NYSE Market Internals

$0.00

(0.00%)

11:16
12/13/19
12/13
11:16
12/13/19
11:16
Technical Analysis
NYSE market internals summary »

Volume is average for…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

EXPR

Express

$5.37

-0.26 (-4.62%)

11:15
12/13/19
12/13
11:15
12/13/19
11:15
Options
Express put volume heavy and directionally bearish »

Bearish flow noted in…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

CSVI

Computer Services

$0.00

(0.00%)

11:13
12/13/19
12/13
11:13
12/13/19
11:13
Hot Stocks
Computer Services names Brian K. Brown as permament CFO »

Computer Services…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

UBER

Uber

$28.60

-0.08 (-0.28%)

11:10
12/13/19
12/13
11:10
12/13/19
11:10
Periodicals
Uber submits appeal to restore taxi license in London, Reuters reports »

Uber has submitted an…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 06

    Jan

SNAP

Snap

$14.78

0.33 (2.28%)

, REGN

Regeneron

$376.32

4.22 (1.13%)

11:08
12/13/19
12/13
11:08
12/13/19
11:08
On The Fly
Snap upgrade, Sarepta target raises among today's top analyst actions »

Check out today's top…

SNAP

Snap

$14.78

0.33 (2.28%)

REGN

Regeneron

$376.32

4.22 (1.13%)

OIS

Oil States

$16.67

-0.965 (-5.47%)

PTEN

Patterson-UTI

$10.05

-0.33 (-3.18%)

SRPT

Sarepta

$133.84

33.45 (33.32%)

GILD

Gilead

$66.05

-1.59 (-2.35%)

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 06

    Feb

  • 23

    Mar

NUE

Nucor

$57.08

-1.03 (-1.77%)

11:05
12/13/19
12/13
11:05
12/13/19
11:05
Hot Stocks
Nucor raises quarterly cash dividend to 40.25c per share »

The board of directors of…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

APHA

Aphria

$5.40

0.13 (2.47%)

11:05
12/13/19
12/13
11:05
12/13/19
11:05
Options
Aphria call volume above normal and directionally bullish »

Bullish option flow…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

11:00
12/13/19
12/13
11:00
12/13/19
11:00
General news
Today's U.S. reports »

Today's U.S. reports…

GPS

Gap

$16.66

-0.36 (-2.12%)

10:55
12/13/19
12/13
10:55
12/13/19
10:55
Options
Gap put volume heavy and directionally bearish »

Bearish flow noted in Gap…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

10:55
12/13/19
12/13
10:55
12/13/19
10:55
Conference/Events
Federal Reserve Bank of New York president participates in a discussion »

New York Federal Reserve…

SPT

Sprout Social

$0.00

(0.00%)

10:52
12/13/19
12/13
10:52
12/13/19
10:52
Syndicate
Sprout Social indicated to open at $19.25, IPO priced at $17.00 »

Sprout Social (SPT)…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 13

    Dec

SPX

S&P 500

$0.00

(0.00%)

, SPY

SPDR S&P 500 ETF Trust

$317.49

0.35 (0.11%)

10:47
12/13/19
12/13
10:47
12/13/19
10:47
General news
U.S. Trade Representative says Phase One trade deal with China 'enforceable' »

United States Trade…

SPX

S&P 500

$0.00

(0.00%)

SPY

SPDR S&P 500 ETF Trust

$317.49

0.35 (0.11%)

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

UNH

UnitedHealth

$286.83

3.03 (1.07%)

10:45
12/13/19
12/13
10:45
12/13/19
10:45
Options
UnitedHealth call volume above normal and directionally bullish »

Bullish option flow…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

10:45
12/13/19
12/13
10:45
12/13/19
10:45
General news
Breaking General news story  »

New York Federal Reserve…

10:45
12/13/19
12/13
10:45
12/13/19
10:45
General news
Breaking General news story  »

New York Federal Reserve…

ALG

Alamo Group

$117.70

0.51 (0.44%)

10:43
12/13/19
12/13
10:43
12/13/19
10:43
Conference/Events
Alamo Group management to meet with Sidoti »

Meetings to be held in…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 17

    Dec

  • 18

    Dec

ABT

Abbott

$86.48

0.5 (0.58%)

10:40
12/13/19
12/13
10:40
12/13/19
10:40
Hot Stocks
Abbott raises quarterly dividend 12.5% to 36c per share »

The board of directors of…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

EXPO

Exponent

$65.46

-0.62 (-0.94%)

10:37
12/13/19
12/13
10:37
12/13/19
10:37
Conference/Events
Exponent management to meet with Sidoti »

Meeting to be held in…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 18

    Dec

Get Full Fly Access

Breaking market intelligence sent straight to you
Our team of experts analyze every news story and filter out the noise to deliver real-time market moving news.
Up-to-date information on important industry events
Get real-time updates on events that are moving the market—from conferences and calls to syndicate announcements.
News focused on the companies in your portfolio
Create up to 12 portfolios with 150 stocks each, and see how active they are in market news.